Azimuth Capital Management LLC increased its stake in Amgen, Inc. (NASDAQ:AMGN) by 21.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,858 shares of the medical research company’s stock after buying an additional 1,400 shares during the quarter. Azimuth Capital Management LLC’s holdings in Amgen were worth $1,451,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Charter Trust Co. raised its stake in Amgen by 3.4% in the 2nd quarter. Charter Trust Co. now owns 12,634 shares of the medical research company’s stock valued at $2,332,000 after acquiring an additional 414 shares during the period. Mitchell Capital Management Co. raised its stake in Amgen by 193.9% in the 2nd quarter. Mitchell Capital Management Co. now owns 5,498 shares of the medical research company’s stock valued at $1,015,000 after acquiring an additional 3,627 shares during the period. Oppenheimer Asset Management Inc. raised its stake in Amgen by 1.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 41,306 shares of the medical research company’s stock valued at $7,625,000 after acquiring an additional 645 shares during the period. Premier Fund Managers Ltd raised its stake in Amgen by 10.4% in the 2nd quarter. Premier Fund Managers Ltd now owns 20,325 shares of the medical research company’s stock valued at $3,727,000 after acquiring an additional 1,908 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Amgen by 17.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after acquiring an additional 343,690 shares during the period. Institutional investors and hedge funds own 77.23% of the company’s stock.
AMGN stock opened at $196.15 on Friday. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03. The firm has a market cap of $129.33 billion, a price-to-earnings ratio of 15.59, a PEG ratio of 1.95 and a beta of 1.39. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $201.23.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, topping the Zacks’ consensus estimate of $3.52 by $0.31. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $5.73 billion. During the same quarter last year, the business earned $3.27 earnings per share. Amgen’s revenue was up 4.3% on a year-over-year basis. equities analysts expect that Amgen, Inc. will post 13.95 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 7th. Investors of record on Friday, August 17th will be given a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Thursday, August 16th. Amgen’s payout ratio is currently 41.97%.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $184.27, for a total value of $281,011.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.19% of the stock is currently owned by company insiders.
AMGN has been the topic of a number of research analyst reports. TheStreet upgraded Amgen from a “c+” rating to a “b-” rating in a research note on Friday, May 25th. BidaskClub cut Amgen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 19th. Mizuho set a $200.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Tuesday, May 15th. Jefferies Financial Group reiterated a “buy” rating and set a $200.00 price objective on shares of Amgen in a research report on Monday, July 16th. Finally, Morgan Stanley increased their price objective on Amgen from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Friday, July 13th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $202.76.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Article: Investing in Dividend Stocks
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.